News | July 27, 2025
Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
_256_384.jpg)
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
Upgrades 2025 full-year CDMO sales and margin outlook
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Subscribe To Our Newsletter & Stay Updated
